Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03285607
Title MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Recruitment Withdrawn
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine

Her2-receptor negative breast cancer


Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel

Age Groups: adult | senior
Covered Countries

No variant requirements are available.